Author: Galindo-Calvillo, César David; RodrÃguez-Roque, Carlos Saúl; Gómez-De León, Andrés; TarÃn-Arzaga, Luz; Gómez-Almaguer, David
Title: Treating Thrombotic Thrombocytopenic Purpura Without Plasma Exchange During the COVID-19 Pandemic. A Case Report and a Brief Literature Review Cord-id: vovfb54k Document date: 2021_2_27
ID: vovfb54k
Snippet: We report the case of a patient diagnosed with a clinical relapse of acquired immune-mediated thrombotic thrombocytopenic purpura (TTP) who was successfully treated with low-dose rituximab plus corticosteroids without the use of plasma exchange (PEx), which was unavailable at the time due to the COVID-19 pandemic. Rituximab 100 mg weekly for 4 weeks was administered, combined with 1 mg/kg of prednisone, obtaining a complete hematological response in 6 weeks. This case suggests that PEx may be un
Document: We report the case of a patient diagnosed with a clinical relapse of acquired immune-mediated thrombotic thrombocytopenic purpura (TTP) who was successfully treated with low-dose rituximab plus corticosteroids without the use of plasma exchange (PEx), which was unavailable at the time due to the COVID-19 pandemic. Rituximab 100 mg weekly for 4 weeks was administered, combined with 1 mg/kg of prednisone, obtaining a complete hematological response in 6 weeks. This case suggests that PEx may be unnecessary for a subset of patients with relapsed TTP who are clinically stable without significant end-organ damage. A brief literature review regarding TTP patients treated without plasma exchange is also included.
Search related documents:
Co phrase search for related documents, hyperlinks ordered by date